1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

  • July 2015
  • 81 pages
  • Infiniti Research Limited
Report ID: 3155275

Summary

Table of Contents

Search Inside

About Glioblastoma Multiforme
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options.
Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market.
Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

Covered in this Report
The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme.
Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
- Oral
- Parenteral
Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
- Small Molecules
- Biologics
This report includes a discussion on the market in the following three regions:
- The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
- EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India
Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.

Key Regions
- Americas
- EMEA
- APAC
Key Vendors
- Arbor Pharmaceuticals
- Bristol-Myers Squibb
- Eisai
- F. Hoffmann-La Roche
- Merck
Other Prominent Vendors

- AB Science
- Abbvie
- Actelion
- Activartis Biotech
- Advantagene
- Agenus
- Agios
- Amgen
- Angiochem
- Apogenix
- Axelar
- BioNTech
- Boehringer Ingelheim
- Boston Biomedical
- Bristol-Myers Squibb
- Celgene
- Celldex Therapeutics
- ChemoCentryx
- Cortice Biosciences
- CytoVac
- CytRx
- Deciphera
- Del Mar Pharmaceuticals
- Diffusion Pharmaceuticals
- DNATrix
- Eli Lilly
- Epitopoietic Research
- e-Therapeutics
- Exelixis
- G W Pharmaceuticals
- Genspera
- immatics
- ImmunoCellular Therapeutics
- Immunovaccine
- Intrexon
- IRAD Oncology
- Karyopharm Therapeutics
- Kite Pharma
- Life Science Pharmaceuticals
- Medicenna Therapeutics
- Merck
- Merrimack Pharmaceuticals
- Nektar Therapeutics
- Northwest Biotherapeutics
- Novartis
- Noxxon
- OncoSynergy
- Oncovir
- Ono Pharmaceutical
- Peregrine Pharmaceuticals
- Plexxikon
- Sanofi
- Seattle Genetics
- Spectrum Pharmaceuticals
- Stemline Therapeutics
- Tocagen
- Tracon Pharma
- TVAX Biomedical
- VBL Therapeutics
- Virttu Biologics
- Ziopharm Oncology
Market Driver
- Lack of Treatment Options for Glioblastoma Multiforme
- For a full and detailed list, view our report
Market Challenge
- Use of Off-label Drugs
- For a full and detailed list, view our report
Market Trend
- Prospective Entry of Novel Agents
- For a full and detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.